1887

Abstract

There are no widely available vaccines or antiviral drugs capable of protecting against infection with Venezuelan equine encephalitis virus (VEEV), although an adenovirus vector expressing VEEV structural proteins protects mice from challenge with VEEV and is potentially a vaccine suitable for human use. This work examines whether alpha interferon (IFN-) could act as an adjuvant for the adenovirus-based vaccine. IFN- was either expressed by a plasmid linked to the adenovirus vaccine or encoded by a separate adenovirus vector administered as a mixture with the vaccine. In contrast to previous reports with other vaccines, the presence of IFN- reduced the antibody response to VEEV. When IFN- was encoded by adenovirus, the lack of a VEEV-specific response was accompanied by an increase in the immune response to the adenovirus vector. IFN- also plays a direct role in defence against virus infection, inducing the expression of a large number of antiviral proteins. Adenovirus-delivered IFN- protected mice from VEEV disease when administered 24 h prior to challenge, but not when administered 6 h post-challenge, suggesting that up to 24 h is required for the development of the IFN-mediated antiviral response.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.006833-0
2009-04-01
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/90/4/874.html?itemId=/content/journal/jgv/10.1099/vir.0.006833-0&mimeType=html&fmt=ahah

References

  1. Alevizatos, A. C., McKinney, R. W. & Feigin, R. D. ( 1967; ). Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man. Am J Trop Med Hyg 16, 762–768.
    [Google Scholar]
  2. Bennett, A. M., Elvin, S. J., Wright, A. J., Jones, S. M. & Phillpotts, R. J. ( 2000; ). An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 19, 337–347.[CrossRef]
    [Google Scholar]
  3. Berge, T. O., Gleiser, C. A., Gochenour, W. S., Jr, Miesse, M. L. & Tigertt, W. D. ( 1961; ). Studies on the virus of Venezuelan equine encephalomyelitis. II. Modification by specific immune serum of response of central nervous system of mice. J Immunol 87, 509–517.
    [Google Scholar]
  4. Bracci, L., Canini, I., Puzelli, S., Sestili, P., Venditti, M., Spada, M., Donatelli, I., Belardelli, F. & Proietti, E. ( 2005; ). Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23, 2994–3004.[CrossRef]
    [Google Scholar]
  5. Butcher, W. & Ulaeto, D. ( 2005; ). Contact inhibition of orthopoxviruses by household disinfectants. J Appl Microbiol 99, 279–284.[CrossRef]
    [Google Scholar]
  6. Casamassima, A. C., Hess, L. W. & Marty, A. ( 1987; ). TC-83 Venezuelan equine encephalitis vaccine exposure during pregnancy. Teratology 36, 287–289.[CrossRef]
    [Google Scholar]
  7. Chinsangaram, J., Moraes, M. P., Koster, M. & Grubman, M. J. ( 2003; ). Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J Virol 77, 1621–1625.[CrossRef]
    [Google Scholar]
  8. de Avila Botton, S., Brum, M. C. S., Bautista, E., Koster, M., Weiblen, R., Golde, W. T. & Grubman, M. J. ( 2006; ). Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 24, 3446–3456.[CrossRef]
    [Google Scholar]
  9. Dubois, E., Merle, G., Roquier, C., Trompette, A., Le Guyader, F., Crucière, C. & Chomel, J.-J. ( 2004; ). Diversity of enterovirus sequences detected in oysters by RT-heminested PCR. Int J Food Microbiol 92, 35–43.[CrossRef]
    [Google Scholar]
  10. Garmashova, N., Gorchakov, R., Volkova, E., Paessler, S., Frolova, E. & Frolov, I. ( 2007; ). The old world and new world alphaviruses use different virus-specific proteins for induction of transcriptional shutoff. J Virol 81, 2472–2484.[CrossRef]
    [Google Scholar]
  11. Greenway, T. E., Eldridge, J. H., Ludwig, G., Staas, J. K., Smith, J. F., Gilley, R. M. & Michalek, S. M. ( 1998; ). Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine. Vaccine 16, 1314–1323.[CrossRef]
    [Google Scholar]
  12. Grieder, F. B. & Vogel, S. N. ( 1999; ). Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Virology 257, 106–118.[CrossRef]
    [Google Scholar]
  13. Hilleman, M. R. ( 2002; ). Overview: cause and prevention in biowarfare and bioterrorism. Vaccine 20, 3055–3067.[CrossRef]
    [Google Scholar]
  14. Hodgson, L. A., Ludwig, G. V. & Smith, J. F. ( 1999; ). Expression, processing and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine 17, 1151–1160.[CrossRef]
    [Google Scholar]
  15. Hunt, A. R., Frederickson, S., Hinkel, C., Bowdish, K. S. & Roehrig, J. T. ( 2006; ). A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol 87, 2467–2476.[CrossRef]
    [Google Scholar]
  16. Johnson, K. M. & Martin, D. H. ( 1974; ). Venezuelan equine encephalitis. Adv Vet Sci Comp Med 18, 79–116.
    [Google Scholar]
  17. Kinney, R. M., Esposito, J. J., Mathews, J. H., Johnson, B. J. B., Roehrig, J. T., Barrett, A. D. T. & Trent, D. W. ( 1988; ). Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol 62, 4697–4702.
    [Google Scholar]
  18. Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F. & Tough, D. F. ( 2001; ). Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461–470.[CrossRef]
    [Google Scholar]
  19. Lukaszewski, R. A. & Brooks, T. J. G. ( 2000; ). Pegylated alpha interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J Virol 74, 5006–5015.[CrossRef]
    [Google Scholar]
  20. Mathews, J. H. & Roehrig, J. T. ( 1982; ). Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. J Immunol 129, 2763–2767.
    [Google Scholar]
  21. Mathews, J. H., Roehrig, J. T. & Trent, D. W. ( 1985; ). Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol 55, 594–600.
    [Google Scholar]
  22. O'Brien, L. ( 2007; ). Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs. Antiviral Res 75, 20–29.[CrossRef]
    [Google Scholar]
  23. Paessler, S., Ni, H., Petrakova, O., Fayzulin, R. Z., Yun, N., Anishchenko, M., Weaver, S. C. & Frolov, I. ( 2006; ). Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J Virol 80, 2784–2796.[CrossRef]
    [Google Scholar]
  24. Paessler, S., Yun, N. E., Judy, B. M., Dziuba, N., Zacks, M. A., Grund, A. H., Frolov, I., Campbell, G. A., Weaver, S. C. & Estes, D. M. ( 2007; ). Alpha–beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. Virology 367, 307–323.[CrossRef]
    [Google Scholar]
  25. Paessler, S., Rijnbrand, R., Stein, D. A., Ni, H., Yun, N. E., Dziuba, N., Borisevich, V., Seregin, A., Ma, Y. & other authors ( 2008; ). Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology 376, 357–370.[CrossRef]
    [Google Scholar]
  26. Perkins, S. D., Hartley, M. J., Lukaszewski, R. A., Phillpotts, R. J., Stevenson, F. K. & Bennett, A. M. ( 2005; ). VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine 23, 1931–1940.[CrossRef]
    [Google Scholar]
  27. Phillpotts, R. J. ( 1999; ). Immunity to airborne challenge with Venezuelan equine encephalitis virus develops rapidly after immunisation with the attenuated vaccine strain TC-83. Vaccine 17, 2429–2435.[CrossRef]
    [Google Scholar]
  28. Phillpotts, R. J. ( 2006; ). Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Res 120, 107–112.[CrossRef]
    [Google Scholar]
  29. Phillpotts, R. J., Lescott, T. L. & Jacobs, S. C. ( 2000; ). Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV. Acta Virol 44, 233–239.
    [Google Scholar]
  30. Phillpotts, R. J., Jones, L. D. & Howard, S. C. ( 2002; ). Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 20, 1497–1504.[CrossRef]
    [Google Scholar]
  31. Phillpotts, R. J., O'Brien, L., Appleton, R. E., Carr, S. & Bennett, A. ( 2005; ). Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 23, 1615–1623.[CrossRef]
    [Google Scholar]
  32. Pittman, P. R., Makuch, R. S., Mangiafico, J. A., Cannon, T. L., Gibbs, P. H. & Peters, C. J. ( 1996; ). Long-term duration of detectable neutralising antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14, 337–343.[CrossRef]
    [Google Scholar]
  33. Pratt, W. D., Davis, N. L., Johnston, R. E. & Smith, J. F. ( 2003; ). Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 21, 3854–3862.[CrossRef]
    [Google Scholar]
  34. Proietti, E., Bracci, L., Puzelli, S., Di Pucchio, T., Sestili, P., De Vincenzi, E., Venditti, M., Capone, I., Seif, I. & other authors ( 2002; ). Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169, 375–383.[CrossRef]
    [Google Scholar]
  35. Rayfield, E. J., Gorelkin, L., Curnow, R. T. & Jahrling, P. B. ( 1976; ). Virus-induced pancreatic disease by Venezuelan encephalitis virus. Alterations in glucose tolerance and insulin release. Diabetes 25, 623–631.[CrossRef]
    [Google Scholar]
  36. Weaver, S. C., Ferro, C., Barrera, R., Boshell, J. & Navarro, J. C. ( 2004; ). Venezuelan equine encephalitis. Annu Rev Entomol 49, 141–174.[CrossRef]
    [Google Scholar]
  37. Wei, S. K., Colecraft, H. M., DeMaria, C. D., Peterson, B. Z., Zhang, R., Kohout, T. A., Rogers, T. B. & Yue, D. T. ( 2000; ). Ca2+ channel modulation by recombinant auxiliary β subunits expressed in young adult heart cells. Circ Res 86, 175–184.[CrossRef]
    [Google Scholar]
  38. White, L. J., Wang, J. G., Davis, N. L. & Johnston, R. E. ( 2001; ). Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5′ untranslated region. J Virol 75, 3706–3718.[CrossRef]
    [Google Scholar]
  39. Wright, A. J. & Phillpotts, R. J. ( 1998; ). Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice. Arch Virol 143, 1155–1162.[CrossRef]
    [Google Scholar]
  40. Wu, J. Q. H., Barabe, N. D., Huang, Y. M., Rayner, G. A., Christopher, M. E. & Schmaltz, F. L. ( 2007; ). Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology 369, 206–213.[CrossRef]
    [Google Scholar]
  41. Zhang, Y., Burke, C. W., Ryman, K. D. & Klimstra, W. B. ( 2007; ). Identification and characterisation of interferon-induced proteins that inhibit alphavirus replication. J Virol 81, 11246–11255.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.006833-0
Loading
/content/journal/jgv/10.1099/vir.0.006833-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error